F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–35.
20.Raffi F, Rachlis A, Brinson C, Arasteh K, Górgolas M, Brennan C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. Aids [Internet]. 2015;29(2):167–74. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002030-201501140-00004
21.Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, et al. Psychiatric Symptoms in Patients Receiving Dolutegravir. JAIDS J Acquir Immune Defic Syndr [Internet]. 2016;74(4):1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00126334-900000000-97064
22.Rutherford GW, Horvath H. Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as initial antiretroviral therapy for people with HIV: A systematic review. PLoS One. 2016;11(10):1–13.
23.Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks. Clin Drug Investig. 2015;35(3):211–9.
24.Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807–16.
25.Rockstroh J, DeJesus E, Saag M, Yazdanpanah Y, Lennox JL, Wan H, et al. Long-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treatment-naive HIV-1-infected patients: final 5-year double-blind results from STARTMRK. AIDS 2012 XIX Int AIDS Conf Washington, DC, USA July 22-27, 2012. 2012;Poster# LBPE19.
26.Arathoon E, Schneider S, Baraldi E, Lim PL, Opravil M, Van De Casteele T, et al. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. Int J STD AIDS [Internet]. 2013;24(1):12–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23440570
27.Ortiz R, DeJesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. Aids [Internet]. 2008;22(12):1389–97. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002030-200807310-00001
28.Orrell C, Hagins D, Belonosova E, Porteiro N, Walmsley S, Falcó V, et al. Superior Efficacy of Dolutegravir / Abacavir / Lamivudine Fixed Dose Combination Compared With Ritonavir Boosted Atazanavir Plus Tenofovir / Emtricitabine in Treatment-Naive Women With HIV-1 Infection ( ARIA Study ). 2016;2016.
29.Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli SC. Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food. JAIDS J Acquir Immune Defic Syndr [Internet]. 2014;66(4):393–8. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00126334-201408010-00007
30.Zolopa AR, Andersen J, Komarow L, Sanne I, Sanchez A, Hogg E, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLoS One. 2009;4(5).
31.Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV [Internet]. 2016;3(9):e410–20. Available from: http://dx.doi.org/10.1016/S2352-3018(16)30016-9
32.Rockstroh JK, DeJesus E, Henry K, Molina J-M, Gathe J, Ramanathan S, et al. A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection. JAIDS J Acquir Immune Defic Syndr [Internet]. 2013;62(5):483–6. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00126334-201304150-00002
33.Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, Mccomsey GA, Godfrey C, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60(12):1842–51.
34.Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV. 2016;3(11):e510–20.
35.Mark Wainberg M. The Absence of Drug Resistance against Dolutegravir in First-Line Therapy is Attributable to Reduced Viral Replicative Fitness. JAIDS J Acquir Immune Defic Syndr. 2017;74(p 66):1–101.
36.LiYang, QiLi L-B-Q. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors. Int J Antimicrob Agents. 2019;54(5):547–55.
37.Wainberg MM. I-103 The absence of drug resistance against dolutegravir in first-line therapy is attributable to reduced viral replicative fitness. JAIDS J Acquir Immune Defic Syndr. 2017;74(66):I–103.
38.Zash, Rebecca, Joseph Makhema RS. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception Rebecca. N Engl J Med. 379(10):979–81.
39.Zash R, Homes L., Diseko M. JD et al. Neural-tube defects and Antiretroviral treatment Regímenes in Botswana. N Engl J Med. 2019;391(9):827–40.
40.Zash R, Homes L., Diseko M. JD et al. MOAX0105LB - Oral Abstract. IAS 2019. Mexico: IAS 2019; 2019. p. 105.
41.Raesima M. et al. Dolutegravir Use at Conception — Additional Surveillance Data from Botswana. N Engl J Med. 381(9):885–7.
42.Pereira G. et. No ocurrences of neural tube defectos among 382 women on dolutegravir at pregnacy. Abstract. Mexico IAS 2019; 2019. p. Abstract MOAX0104LB.
43.The World Health Organisation. WHO. Statement on DTG - Geneva. Geneve; 2018. p. 1–2.
44.World Health Organization (WHO). Update of first and second line antiretroviral regimens. Who. 2019;(July).
45.Society EACS. Guidelines. Version 10.0 November 2019. London: 2019; 2019. p. 0–122.
46.AIDSinfo. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Dep Heal Hum Serv [Internet]. 2018;298. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
47.Antiviral Society- USA Panel. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel. JAMA - J Am Med Assoc. 2018;320(4):379–96.
48.Cahn P, Rolón MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017;20(1):1–7.
49.Cahn Pet al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovirdisoproxilfumarate and emtricitabine
